本页面由Tiger Trade Technology Pte. Ltd.提供服务

PROTEOMICS INTERNATIONAL LAB

0.130
+0.0054.00%
成交量:3.13万
成交额:4,074
市值:2,146.51万
市盈率:-2.50
高:0.130
开:0.130
低:0.130
收:0.125
52周最高:0.860
52周最低:0.098
股本:1.65亿
流通股本:1.22亿
量比:0.39
换手率:0.03%
股息:- -
股息率:- -
每股收益(TTM):-0.052
每股收益(LYR):-0.064
净资产收益率:-92.99%
总资产收益率:-46.46%
市净率:3.70
市盈率(LYR):-2.04

数据加载中...

公司资料

公司名字:
PROTEOMICS INTERNATIONAL LAB
交易所:
ASX
成立时间:
2001
员工人数:
- -
公司地址:
Harry Perkins Institute of Medical Research,6 Verdun Street,Nedlands,Western Australia,Australia
邮编:
6009
传真:
- -
简介:
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute to enhance diagnosis and treatment of lung conditions, such as asthma and chronic obstructive pulmonary disease; and the Janssen Research & Development, LLC for the research of diabetic kidney and heart disease treatment. The company was founded in 2001 and is based in Perth, Australia.